↓ Skip to main content

Dove Medical Press

Article Metrics

Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa

Overview of attention for article published in Clinical, Cosmetic and Investigational Dermatology, October 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
30 Mendeley
Title
Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa
Published in
Clinical, Cosmetic and Investigational Dermatology, October 2016
DOI 10.2147/ccid.s93619
Pubmed ID
Authors

Christina Fotiadou, Efstratios Vakirlis, Dimitrios Ioannides

Abstract

Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin disease that affects the hair follicles of the aprocrine gland-bearing anatomical areas of the body. It is characterized by deep painful nodules and abscesses that rupture and contribute to the formation of sinus tracks and scarring. The management of HS is based on the assessment of disease severity and a combination of medical and surgical treatment according to the European Guidelines. Adalimumab, a recombinant, fully humanized, anti-tumor necrosis factor alpha (anti-TNF-α) monoclonal antibody, is the only officially approved treatment for the management of moderate-to-severe HS. Case reports, concerning 42 patients who received adalimumab for severe HS (with the standard dose regimen for psoriasis), reported a cumulative response rate of 58% (≥50% in 23 patients) with a relapse rate of 71% (10 out of 14 patients). The most recent and most well-powered phase III, randomized placebo-controlled trials for the evaluation of the efficacy and safety of adalimumab in treatment of moderate-to-severe HS (PIONEER studies I and II) showed that the Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 12 was significantly higher for patients randomized to adalimumab compared to placebo. Adverse events were comparable to placebo. In conclusion, adalimumab, to date, holds the most robust data regarding treatment efficacy in HS. Larger, registry-based studies are needed to further establish the efficacy and safety profile of this anti-TNF-α agent in HS.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 30 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 13%
Student > Master 4 13%
Student > Doctoral Student 3 10%
Other 3 10%
Student > Postgraduate 3 10%
Other 7 23%
Unknown 6 20%
Readers by discipline Count As %
Medicine and Dentistry 18 60%
Chemistry 2 7%
Agricultural and Biological Sciences 2 7%
Biochemistry, Genetics and Molecular Biology 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 1 3%
Unknown 5 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2016.
All research outputs
#4,375,776
of 8,606,703 outputs
Outputs from Clinical, Cosmetic and Investigational Dermatology
#133
of 228 outputs
Outputs of similar age
#127,768
of 249,699 outputs
Outputs of similar age from Clinical, Cosmetic and Investigational Dermatology
#10
of 15 outputs
Altmetric has tracked 8,606,703 research outputs across all sources so far. This one is in the 46th percentile – i.e., 46% of other outputs scored the same or lower than it.
So far Altmetric has tracked 228 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 249,699 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.